8-K: Immix Biopharma Reports Strong CAR-T Trial Results

Immix Biopharma announced a 95% complete response rate in its Phase 2 NEXICART-2 trial for AL Amyloidosis, with all MRD-negative patients achieving CR.

Summary

• Immix Biopharma announced an update on its Phase 2 NEXICART-2 clinical trial for relapsed/refractory AL Amyloidosis.
• All four patients who were MRD-negative at the American Society of Hematology 2025 Annual Meeting (ASH 2025) have converted to complete response (CR).
• The overall CR rate in the NEXICART-2 trial is now 95% (19 out of 20 patients).
• All patients achieving CR did so within one year of follow-up post-dosing.
• No relapses have been observed to date in patients who have reached CR.
• MRD-negativity (10-5) was achieved within 30 days for all MRD-negative patients.
• As of May 14, 2025, 17 out of 20 patients showed rapid normalization of diseased light chains, with a median time to initial response of 7 days.
• Safety data remains consistent with previous observations.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive development due to the strong clinical trial results, high response rates, and promising durability, indicating significant potential for NXC-201.

Positives

• Achieved a 95% complete response (CR) rate in the NEXICART-2 trial, with 19 out of 20 patients responding.
• All four previously announced MRD-negative patients have converted to CR.
• All CRs were achieved within one year of follow-up post-dosing.
• No relapses have been observed to date in patients who have achieved CR.
• MRD-negativity was achieved within 30 days for all MRD-negative patients.
• Rapid normalization of diseased light chains observed in 17 out of 20 patients, with a median time to initial response of 7 days.
• NXC-201 has received Breakthrough Therapy Designation (BTD), Regenerative Medicine Advanced Therapy (RMAT), and Orphan Drug Designation (ODD) from the FDA and EMA.

Negatives

• Interim data from clinical trials are subject to the risk that final results may differ materially from interim findings.
• Regulatory agencies may disagree with the analysis or interpretation of interim data.

Risks

• Final results of clinical trials may differ materially from interim data.
• Third parties, including regulatory agencies, may disagree with the analysis and interpretation of interim data.
• The number of patients in the U.S. with relapsed/refractory AL Amyloidosis and the market size estimates may not be accurate.
• Breakthrough Therapy designation may not expedite the development of NXC-201.
• Further data from ongoing clinical trials may not be favorably consistent with current readouts.
• The company may not be able to continue the NEXICART-2 trial or advance to registration-enabling studies.
• Success in early clinical trials does not ensure success in subsequent trials.
• The company may not be able to obtain additional working capital to continue clinical trials.

Future Outlook

The company plans to initiate a multi-center, randomized Phase 3 trial of NXC-201 in newly diagnosed AL Amyloidosis patients in the first half of 2027. An update from the NEXICART-2 trial is expected in late September 2026, with 1-year follow-up data anticipated by the end of March 2027, which is expected to drive BLA submission and commercial launch.

Management Comments

• "Even in a heavily pretreated population of median 4 prior lines of therapy, we are pleased that NXC-201, as a 5th line of therapy, drives MRD-negativity, converting to durable CRs to-date, indicating that NXC-201 can eliminate the source of toxic light chains that clog up the heart, kidney and liver, causing organ failure and death in relapsed/refractory AL Amyloidosis."
• "As a potential frontline therapy in AL Amyloidosis, we believe there's potential to transform a usual 2-year treatment, into a one-and-done: NXC-201."
• "We have observed the NEXICART-2 CR rate improving over time. In September 2026 we plan to present updated data from our ongoing NEXICART-2 trial. By end of March 2027, we expect to present 1-year follow-up data of enrolled patients, which we expect will drive BLA submission and commercial launch."

Industry Context

StockSavvy.ai notes that Immix Biopharma's update on NXC-201 demonstrates significant progress in the CAR-T therapy space for AL Amyloidosis, a field with substantial unmet need and growing market potential. The reported high CR rates and durability are encouraging, positioning the company to advance towards later-stage trials and potential commercialization, which aligns with broader industry trends of developing targeted and potentially curative therapies for hematological malignancies.

Stakeholder Impact

• Shareholders: Positive impact expected due to strong clinical data potentially leading to future BLA submission and commercialization, increasing company value.
• Patients: Significant positive impact as NXC-201 shows high efficacy and durability in treating a devastating disease with limited options.
• Healthcare Providers: Potential for a new, effective treatment option for relapsed/refractory AL Amyloidosis patients.

Next Steps

• Present updated data from the NEXICART-2 trial in late September 2026.
• Present 1-year follow-up data of enrolled patients by the end of March 2027.
• Initiate a multi-center, randomized Phase 3 trial of NXC-201 in newly diagnosed AL Amyloidosis patients in the first half of 2027.
• Drive BLA submission and commercial launch based on 1-year follow-up data.

Key Dates

Recommendation

The strong efficacy data, high CR rates, durable responses, and rapid achievement of MRD-negativity in the NEXICART-2 trial for NXC-201 represent a significant advancement in AL Amyloidosis treatment. Coupled with favorable regulatory designations and clear plans for Phase 3 trials and potential BLA submission, the outlook for Immix Biopharma is highly positive, warranting a strong buy recommendation.

Keywords

AL Amyloidosis, NXC-201, CAR-T, Clinical Trial, NEXICART-2, Complete Response, MRD-negative, Biopharmaceutical